Logo image of TRAW

TRAWS PHARMA INC (TRAW) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TRAW - US68232V8845 - Common Stock

1.13 USD
-0.04 (-3.42%)
Last: 12/29/2025, 8:22:33 PM
1.1225 USD
-0.01 (-0.66%)
After Hours: 12/29/2025, 8:22:33 PM
Fundamental Rating

4

Taking everything into account, TRAW scores 4 out of 10 in our fundamental rating. TRAW was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of TRAW is average, but there are quite some concerns on its profitability. TRAW is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year TRAW was profitable.
TRAW had a negative operating cash flow in the past year.
TRAW had negative earnings in each of the past 5 years.
In the past 5 years TRAW always reported negative operating cash flow.
TRAW Yearly Net Income VS EBIT VS OCF VS FCFTRAW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of TRAW (777.75%) is better than 100.00% of its industry peers.
TRAW's Return On Equity of 2051.21% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 777.75%
ROE 2051.21%
ROIC N/A
ROA(3y)-116.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRAW Yearly ROA, ROE, ROICTRAW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

TRAW's Profit Margin of 3279.34% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
TRAW does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 3279.34%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRAW Yearly Profit, Operating, Gross MarginsTRAW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

5

2. Health

2.1 Basic Checks

TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRAW has more shares outstanding
There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRAW Yearly Shares OutstandingTRAW Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
TRAW Yearly Total Debt VS Total AssetsTRAW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

TRAW has an Altman-Z score of -77.10. This is a bad value and indicates that TRAW is not financially healthy and even has some risk of bankruptcy.
TRAW's Altman-Z score of -77.10 is on the low side compared to the rest of the industry. TRAW is outperformed by 95.29% of its industry peers.
There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -77.1
ROIC/WACCN/A
WACC9.34%
TRAW Yearly LT Debt VS Equity VS FCFTRAW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.22 indicates that TRAW should not have too much problems paying its short term obligations.
TRAW's Current ratio of 1.22 is on the low side compared to the rest of the industry. TRAW is outperformed by 81.15% of its industry peers.
A Quick Ratio of 1.22 indicates that TRAW should not have too much problems paying its short term obligations.
TRAW has a Quick ratio of 1.22. This is in the lower half of the industry: TRAW underperforms 73.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 1.22
TRAW Yearly Current Assets VS Current LiabilitesTRAW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

TRAW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 119.99%, which is quite impressive.
TRAW shows a strong growth in Revenue. In the last year, the Revenue has grown by 1159.29%.
EPS 1Y (TTM)119.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
Revenue 1Y (TTM)1159.29%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

TRAW is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.82% yearly.
TRAW is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 384.76% yearly.
EPS Next Y99.97%
EPS Next 2Y40.89%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue Next Year1117.39%
Revenue Next 2Y-41.42%
Revenue Next 3Y384.76%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TRAW Yearly Revenue VS EstimatesTRAW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 5M 10M 15M 20M 25M
TRAW Yearly EPS VS EstimatesTRAW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50K -100K -150K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 0.04 indicates a rather cheap valuation of TRAW.
Based on the Price/Earnings ratio, TRAW is valued cheaper than 99.48% of the companies in the same industry.
When comparing the Price/Earnings ratio of TRAW to the average of the S&P500 Index (26.84), we can say TRAW is valued rather cheaply.
TRAW is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.04
Fwd PE N/A
TRAW Price Earnings VS Forward Price EarningsTRAW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRAW Per share dataTRAW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TRAW's earnings are expected to grow with 25.82% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y40.89%
EPS Next 3Y25.82%

More info and screens

0

5. Dividend

5.1 Amount

TRAW does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TRAWS PHARMA INC

NASDAQ:TRAW (12/29/2025, 8:22:33 PM)

After market: 1.1225 -0.01 (-0.66%)

1.13

-0.04 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13
Earnings (Next)03-30 2026-03-30/amc
Inst Owners15.99%
Inst Owner Change3.25%
Ins Owners5.4%
Ins Owner Change4.88%
Market Cap9.03M
Revenue(TTM)2.85M
Net Income(TTM)93.33M
Analysts82.86
Price Target8.16 (622.12%)
Short Float %4.6%
Short Ratio0.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2132.84%
Min Revenue beat(2)-100%
Max Revenue beat(2)4365.69%
Revenue beat(4)1
Avg Revenue beat(4)1064.22%
Min Revenue beat(4)-100%
Max Revenue beat(4)4365.69%
Revenue beat(8)1
Avg Revenue beat(8)527.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-94.67%
PT rev (3m)-94.67%
EPS NQ rev (1m)80.02%
EPS NQ rev (3m)80.02%
EPS NY rev (1m)99.89%
EPS NY rev (3m)99.89%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)1117.39%
Revenue NY rev (3m)1117.39%
Valuation
Industry RankSector Rank
PE 0.04
Fwd PE N/A
P/S 3.17
P/FCF N/A
P/OCF N/A
P/B 2.2
P/tB 5.9
EV/EBITDA N/A
EPS(TTM)28.26
EY2500.88%
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-2.38
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.36
BVpS0.51
TBVpS0.19
PEG (NY)0
PEG (5Y)N/A
Graham Number18.06
Profitability
Industry RankSector Rank
ROA 777.75%
ROE 2051.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3279.34%
GM N/A
FCFM N/A
ROA(3y)-116.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.22
Quick Ratio 1.22
Altman-Z -77.1
F-Score6
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
EPS Next Y99.97%
EPS Next 2Y40.89%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue 1Y (TTM)1159.29%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year1117.39%
Revenue Next 2Y-41.42%
Revenue Next 3Y384.76%
Revenue Next 5YN/A
EBIT growth 1Y34.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.67%
OCF growth 3YN/A
OCF growth 5YN/A

TRAWS PHARMA INC / TRAW FAQ

What is the fundamental rating for TRAW stock?

ChartMill assigns a fundamental rating of 4 / 10 to TRAW.


Can you provide the valuation status for TRAWS PHARMA INC?

ChartMill assigns a valuation rating of 4 / 10 to TRAWS PHARMA INC (TRAW). This can be considered as Fairly Valued.


Can you provide the profitability details for TRAWS PHARMA INC?

TRAWS PHARMA INC (TRAW) has a profitability rating of 3 / 10.


What is the financial health of TRAWS PHARMA INC (TRAW) stock?

The financial health rating of TRAWS PHARMA INC (TRAW) is 5 / 10.